Override of the Osteoclast Defect in Osteopontin-Deficient Mice by Metastatic Tumor Growth in the Bone
Open Access
- 28 February 2006
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 168 (2), 551-561
- https://doi.org/10.2353/ajpath.2006.050480
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivityPharmacology Biochemistry and Behavior, 2004
- Osteopontin as a Mediator of NKT Cell Function in T Cell-Mediated Liver DiseasesImmunity, 2004
- Role of osteopontin in tumour progressionBritish Journal of Cancer, 2004
- Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient miceCellular Immunology, 2004
- Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude miceClinical & Experimental Metastasis, 2004
- Osteopontin Expression by Osteoclast and Osteoblast Progenitors in the Murine Bone Marrow: Demonstration of Its Requirement for Osteoclastogenesis and Its Increase After Ovariectomy*Endocrinology, 1997
- Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.JCI Insight, 1996
- Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: An in vitro and ex vivo study of remodeling boneJournal of Bone and Mineral Research, 1995
- Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.1994
- A murine model of experimental metastasis to bone and bone marrow.1988